PE20151072A1 - Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa - Google Patents

Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa

Info

Publication number
PE20151072A1
PE20151072A1 PE2015000674A PE2015000674A PE20151072A1 PE 20151072 A1 PE20151072 A1 PE 20151072A1 PE 2015000674 A PE2015000674 A PE 2015000674A PE 2015000674 A PE2015000674 A PE 2015000674A PE 20151072 A1 PE20151072 A1 PE 20151072A1
Authority
PE
Peru
Prior art keywords
cycloalkylene
compounds
tiadiazol
bis
derivatives
Prior art date
Application number
PE2015000674A
Other languages
English (en)
Inventor
Rene M Lemieux
Janeta Popovici-Muller
Francesco G Salituro
Jeffrey O Saunders
Jeremy M Travins
Yongsheng Chen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of PE20151072A1 publication Critical patent/PE20151072A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Abstract

En la presente se describen compuestos y composiciones que comprenden compuestos que inhiben la glutaminasa. En la presente tambien se describen metodos para emplear los compuestos que inhiben la glutaminasa en el tratamiento del cancer. Los compuestos de la invencion son de formula (I), donde X es cicloalquileno C3-C7; W, Y y Z son S, etc; R1, R2 son NH2, etc; R3 es H, etc, R6 es H, etc, m y n son 0, 1 o 2, o y p son 1, 2 o 3. Los compuestos preferidos son (S)-N-(5-((1S,3S)-3-(5-(2-(6-(3,3-difluoroazetidin-1-il)piridin-2-il)acetamido)-1,3,4-tiadiazol-2-il) ciclohexil)-1, 3, 4-tiadiazol-2-il) -2-hidroxi-2-fenilacetamida; 2-(6-(3,3-difluoroazetidin-1-il) piridin-2-il)-N-(5-((1S, 3S)-3-(5-(2-(3-(trifluorometoxi) fenil)acetamido)-1, 3, 4-tiadiazol-2-il) ciclohexil) -1, 3, 4-tiadiazol-2-il) acetamida
PE2015000674A 2012-11-22 2013-11-21 Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa PE20151072A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
PCT/CN2013/001428 WO2014079150A1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use

Publications (1)

Publication Number Publication Date
PE20151072A1 true PE20151072A1 (es) 2015-08-26

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000674A PE20151072A1 (es) 2012-11-22 2013-11-21 Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa

Country Status (36)

Country Link
US (2) US10087172B2 (es)
EP (2) EP2922850B1 (es)
JP (2) JP6333277B2 (es)
KR (1) KR20150085079A (es)
CN (2) CN108727307A (es)
AR (1) AR093598A1 (es)
AU (2) AU2013347771B2 (es)
BR (1) BR112015011830A2 (es)
CA (1) CA2893510C (es)
CL (1) CL2015001392A1 (es)
CR (1) CR20150316A (es)
CY (1) CY1120581T1 (es)
DK (1) DK2922850T3 (es)
EA (2) EA201890754A1 (es)
EC (1) ECSP15026557A (es)
ES (1) ES2690390T3 (es)
HK (1) HK1214593A1 (es)
HR (1) HRP20181628T1 (es)
HU (1) HUE040111T2 (es)
IL (1) IL238958B (es)
LT (1) LT2922850T (es)
MX (1) MX367389B (es)
MY (1) MY177344A (es)
NZ (1) NZ708382A (es)
PE (1) PE20151072A1 (es)
PH (2) PH12015501150B1 (es)
PL (1) PL2922850T3 (es)
PT (1) PT2922850T (es)
RS (1) RS57859B1 (es)
SA (1) SA515360469B1 (es)
SG (2) SG10201609940RA (es)
SI (1) SI2922850T1 (es)
TR (1) TR201812360T4 (es)
TW (2) TW201906825A (es)
UA (1) UA117360C2 (es)
WO (3) WO2014079011A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
DK2920168T3 (da) 2012-11-16 2021-10-18 Calithera Biosciences Inc Heterocykliske glutaminase-inhibitorer
US10011574B2 (en) 2012-11-21 2018-07-03 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CN105283182A (zh) * 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
EA035929B1 (ru) 2013-01-15 2020-09-02 Инсайт Холдингс Корпорейшн ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법
EA033919B1 (ru) 2014-04-30 2019-12-10 Пфайзер Инк. Соединённые циклоалкилом дигетероциклические производные
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
BR112016030730B1 (pt) * 2014-07-03 2023-05-02 Board Of Regents, The University Of Texas System Composto
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
MX2017001620A (es) 2014-08-07 2017-05-10 Calithera Biosciences Inc Formas cristalinas de inhibidores de glutaminasa.
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
US10441587B2 (en) 2015-04-06 2019-10-15 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
CN107921044B (zh) 2015-06-30 2022-01-21 德州大学***董事会 用于治疗疾病的gls1抑制剂
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
US10258619B2 (en) 2015-10-05 2019-04-16 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN109503570B (zh) * 2015-12-18 2020-08-25 诺言医药科技(上海)有限公司 一种含有索拉非尼的药物组合物及其应用
CA3009355A1 (en) 2015-12-22 2017-06-29 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
JP2019526560A (ja) * 2016-08-25 2019-09-19 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤との併用療法
RU2020112558A (ru) 2017-10-18 2021-11-18 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Терапия на основе ингибитора глутаминазы
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
WO2020096916A2 (en) 2018-11-08 2020-05-14 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
DK0691962T3 (da) 1993-03-29 2000-10-16 Basf Ag 1-amino-3-phenoxypropanderivater som modulatorer ved multilægemiddelresistens
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
AU768751B2 (en) 1998-06-18 2004-01-08 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
US20030054985A1 (en) 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
DE602006016085D1 (de) 2005-03-16 2010-09-23 Genentech Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
WO2008048967A1 (en) 2006-10-16 2008-04-24 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
MX2010005324A (es) 2007-11-19 2010-06-01 Genentech Inc Composiciones y metodos para inhibir el avance del tumor.
US7951549B2 (en) 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
US20120142028A1 (en) 2009-04-17 2012-06-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2011143160A2 (en) * 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
EP3955004A3 (en) 2010-06-23 2022-05-11 University of Louisville Research Foundation, Inc. Use of fatty acids in methods for detecting cancer
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EP2782570B1 (en) * 2011-11-21 2019-09-18 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
JP2015514062A (ja) 2012-03-15 2015-05-18 ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法
US10011574B2 (en) 2012-11-21 2018-07-03 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법

Also Published As

Publication number Publication date
JP6333277B2 (ja) 2018-05-30
PH12015501150A1 (en) 2015-08-17
TR201812360T4 (tr) 2018-09-21
EP2922850B1 (en) 2018-07-18
US20150291576A1 (en) 2015-10-15
EA030646B1 (ru) 2018-09-28
WO2014079011A1 (en) 2014-05-30
CA2893510C (en) 2021-01-19
LT2922850T (lt) 2018-09-10
US10689375B2 (en) 2020-06-23
PH12017502141A1 (en) 2019-02-27
CA2893510A1 (en) 2014-05-30
EA201590987A1 (ru) 2015-12-30
SG11201504049VA (en) 2015-07-30
MX2015006493A (es) 2015-08-05
DK2922850T3 (en) 2018-10-08
EA201890754A1 (ru) 2018-08-31
EP2922850A4 (en) 2016-05-18
UA117360C2 (uk) 2018-07-25
AU2018202954A1 (en) 2018-05-17
JP2018150316A (ja) 2018-09-27
SI2922850T1 (sl) 2018-10-30
US10087172B2 (en) 2018-10-02
IL238958B (en) 2019-09-26
CN104936954A (zh) 2015-09-23
CL2015001392A1 (es) 2016-04-22
KR20150085079A (ko) 2015-07-22
MX367389B (es) 2019-08-19
HUE040111T2 (hu) 2019-02-28
US20190084976A1 (en) 2019-03-21
EP3456719A1 (en) 2019-03-20
PL2922850T3 (pl) 2018-12-31
BR112015011830A2 (pt) 2017-07-11
ES2690390T3 (es) 2018-11-20
HK1214593A1 (zh) 2016-07-29
PH12015501150B1 (en) 2015-08-17
TWI629268B (zh) 2018-07-11
ECSP15026557A (es) 2016-01-29
CY1120581T1 (el) 2019-07-10
SG10201609940RA (en) 2016-12-29
PT2922850T (pt) 2018-10-15
MY177344A (en) 2020-09-13
RS57859B1 (sr) 2018-12-31
CR20150316A (es) 2015-08-28
TW201427963A (zh) 2014-07-16
CN108727307A (zh) 2018-11-02
AU2013347771A1 (en) 2015-06-11
IL238958A0 (en) 2015-07-30
EP2922850A1 (en) 2015-09-30
CN104936954B (zh) 2018-08-14
WO2014079150A1 (en) 2014-05-30
WO2014079136A1 (en) 2014-05-30
AR093598A1 (es) 2015-06-10
TW201906825A (zh) 2019-02-16
SA515360469B1 (ar) 2017-07-11
AU2013347771B2 (en) 2018-02-01
HRP20181628T1 (hr) 2018-12-14
NZ708382A (en) 2020-04-24
JP2016500082A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
PE20151072A1 (es) Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PH12015502549B1 (en) Heterocyclic derivatives
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
MX2019007080A (es) Compuestos de benzimidazol como inhibidores de c-kit.
NZ709609A (en) Benzylamine derivatives
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20160524A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20161073A1 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
PE20170004A1 (es) Inhibidores de biaril cinasa
MX2016001011A (es) Derivados de quinazolin-4-ona sustituida.
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
MX2015012431A (es) Pirrol amida como inhibidores.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
CY1119118T1 (el) Θεραπευτικος παραγων για τις διαταραχες της διαθεσης
CY1120355T1 (el) Αναστολεις toy iap
UY36749A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen